Eli Lilly and Company (LLY) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Eli Lilly and Company (LLY) trades at a price-to-earnings ratio of 89.9x, with a stock price of $1052.20 and trailing twelve-month earnings per share of $20.49.
The current P/E is 44% above its 5-year average of 62.6x. Over the past five years, LLY's P/E has ranged from a low of 26.1x to a high of 116.1x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, LLY trades at a 279% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
The PEG ratio of 14.62 (P/E divided by 102% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, LLY commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LLY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Large diversified branded pharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
LLYEli Lilly and Company | $942B | 89.9 | 14.62 | +102% |
JNJJohnson & Johnson | $599B | 42.9Lowest | - | -58% |
AZNAstraZeneca PLC | $323B | 63.7 | 2.92Best | +189%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $763.00 | $20.44 | 37.3x | +18% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $779.53 | $15.30 | 50.9x | +60% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $825.91 | $12.29 | 67.2x | +112% |
| FY2024 Q4 | $772.00 | $11.71 | 65.9x | +108% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $885.94 | $9.25 | 95.8x | +202% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $905.38 | $8.12 | 111.5x | +251% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $777.96 | $6.70 | 116.1x | +266% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $582.92 | $5.64 | 103.4x | +225% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $537.13 | $5.26 | 102.1x | +221% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $468.98 | $6.93 | 67.7x | +113% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $343.42 | $6.12 | 56.1x | +77% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $365.84 | $6.70 | 54.6x | +72% |
Average P/E for displayed period: 31.8x
See LLY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LLY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare LLY vs AGIO
See how LLY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is LLY stock overvalued or undervalued?
LLY trades at 89.9x P/E, above its 5-year average of 62.6x. The 75th percentile ranking indicates a premium to historical valuation.
How does LLY's valuation compare to peers?
Eli Lilly and Company P/E of 89.9x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is LLY's PEG ratio?
LLY PEG ratio is 14.62. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2025.